Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading Volume

Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) shares saw an uptick in trading volume on Thursday . 466,723 shares changed hands during mid-day trading, an increase of 96% from the previous session's volume of 237,868 shares.The stock last traded at $21.55 and had previously closed at $21.15.

Wall Street Analysts Forecast Growth

SLN has been the topic of several analyst reports. BMO Capital Markets initiated coverage on Silence Therapeutics in a report on Wednesday, January 31st. They set an "outperform" rating and a $67.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Friday, March 15th. Chardan Capital upped their price target on shares of Silence Therapeutics from $26.00 to $42.00 and gave the company a "buy" rating in a report on Thursday, March 14th. Finally, Morgan Stanley raised their price target on Silence Therapeutics from $29.00 to $45.00 and gave the company an "overweight" rating in a research report on Thursday, March 14th.

Silence Therapeutics Trading Up 5.7 %

The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.56 and a current ratio of 4.56. The company's 50 day moving average is $22.99 and its 200 day moving average is $16.51. The stock has a market capitalization of $669.23 million, a price-to-earnings ratio of -15.31 and a beta of 1.41.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its earnings results on Wednesday, March 13th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.22). Silence Therapeutics had a negative net margin of 171.41% and a negative return on equity of 262.17%. The company had revenue of $2.61 million during the quarter, compared to the consensus estimate of $11.46 million. On average, research analysts forecast that Silence Therapeutics plc will post -1.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Lynx1 Capital Management LP bought a new stake in Silence Therapeutics in the third quarter valued at $2,315,000. UBS Group AG grew its holdings in shares of Silence Therapeutics by 4.8% in the 4th quarter. UBS Group AG now owns 69,006 shares of the company's stock worth $1,052,000 after purchasing an additional 3,191 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Silence Therapeutics during the 4th quarter worth about $450,000. Citadel Advisors LLC bought a new position in Silence Therapeutics during the 4th quarter valued at about $378,000. Finally, Millennium Management LLC lifted its holdings in Silence Therapeutics by 19.8% during the 4th quarter. Millennium Management LLC now owns 17,436 shares of the company's stock valued at $266,000 after purchasing an additional 2,879 shares during the last quarter. Institutional investors own 98.73% of the company's stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.